Lineage Cell Therapeutics, Inc. (TLV: LCTX)

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions ILS. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 19, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	621	687	699	1,284	849	460
Market Cap Growth	-19.31%	-1.77%	-45.56%	51.35%	84.29%	10.71%
Enterprise Value	504	544	471	1,087	732	350
Last Close Price	3.42	3.91	3.92	7.74	5.59	2.83
PS Ratio	19.61	21.32	13.53	95.13	144.57	37.93
PB Ratio	2.64	3.08	2.76	4.54	2.78	1.20
P/TBV Ratio	19.05	30.84	12.45	11.89	6.86	2.47
P/FCF Ratio	-	-	307.85	-	-	-
P/OCF Ratio	-	-	187.79	-	-	-
EV/Sales Ratio	15.45	16.88	9.11	80.50	124.70	28.82
EV/FCF Ratio	-5.88	-	207.31	-	-	-
Debt / Equity Ratio	0.04	0.05	0.05	0.03	0.04	0.05
Debt / FCF Ratio	-	-	6.03	-	-	-
Asset Turnover	0.09	0.08	0.10	0.03	0.02	0.03
Quick Ratio	2.39	2.02	3.06	2.32	5.35	4.78
Current Ratio	2.48	2.14	3.16	2.37	5.66	8.86
Return on Equity (ROE)	-30.50%	-32.07%	-32.37%	-46.52%	-20.05%	-11.62%
Return on Assets (ROA)	-11.84%	-11.80%	-9.44%	-21.78%	-14.16%	-18.59%
Return on Capital (ROIC)	-17.48%	-18.82%	-16.60%	-31.93%	-15.35%	-20.02%
Earnings Yield	-11.76%	-11.26%	-13.21%	-10.42%	-7.82%	-8.78%
FCF Yield	-13.49%	-15.33%	0.32%	-5.79%	-7.51%	-24.29%
Buyback Yield / Dilution	-7.29%	-1.69%	-3.22%	-9.64%	-3.10%	-14.68%
Total Shareholder Return	-7.29%	-1.69%	-3.22%	-9.64%	-3.10%	-14.68%

Source: S&P Capital IQ. Standard template. Financial Sources.